NEUROLOGISK KLINIK ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  5.1% 3.4% 5.6% 4.1% 5.1%  
Credit score (0-100)  45 56 41 48 43  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Gross profit  89.1 259 161 259 100  
EBITDA  89.1 259 319 259 100  
EBIT  25.1 195 240 259 100  
Pre-tax profit (PTP)  16.9 185.8 250.8 897.5 343.9  
Net earnings  13.2 144.7 194.6 699.8 265.9  
Pre-tax profit without non-rec. items  16.9 186 251 898 344  

 
See the entire income statement

Balance sheet (kDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Tangible assets total  136 72.0 0.0 0.0 0.0  
Shareholders equity total  376 521 863 1,450 1,716  
Interest-bearing liabilities  210 239 0.0 102 290  
Balance sheet total (assets)  648 892 1,027 1,919 2,290  

Net Debt  -277 -537 -994 -1,787 -2,001  
 
See the entire balance sheet

Volume 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  89.1 259 161 259 100  
Gross profit growth  -55.8% 190.6% -38.0% 61.2% -61.4%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  648 892 1,027 1,919 2,290  
Balance sheet change%  -4.1% 37.7% 15.2% 86.8% 19.4%  
Added value  89.1 258.9 318.6 337.8 100.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -128 -128 -151 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  3.0 4.0 5.0 5.0 5.0  

Profitability 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  28.2% 75.3% 149.2% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  3.8% 25.3% 26.6% 61.1% 16.9%  
ROI %  4.2% 28.8% 31.5% 74.6% 20.0%  
ROE %  3.6% 32.3% 28.1% 60.5% 16.8%  

Solidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Equity ratio %  58.0% 58.4% 84.0% 75.6% 74.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -310.4% -207.3% -312.1% -690.5% -2,001.7%  
Gearing %  55.9% 45.8% 0.0% 7.0% 16.9%  
Net interest  0 0 0 0 0  
Financing costs %  3.8% 4.0% 3.8% 5.5% 6.4%  

Liquidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Quick Ratio  1.9 2.2 6.3 4.1 4.0  
Current Ratio  1.9 2.2 6.3 4.1 4.0  
Cash and cash equivalent  486.9 775.3 994.4 1,888.6 2,290.5  

Capital use efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  245.8 448.7 634.5 -122.8 -96.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0